Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: To improve immune function
Number of Subjects: 15
Medication: fecal microbial transplant
Location: Connecticut|Massachusetts|New York|Rhode Island
Institutions: Griffin Hospital
130 Division Street
Dr. Joseph B. Guarnaccia
State of Connecticut Department of Public Health
The Yale-Griffin Prevention Research Center, the Multiple Sclerosis Treatment Center at Griffin Hospital, and Yale University are teaming up to study whether changing the bacteria in the gut can affect the process that leads to the development of multiple sclerosis (MS). This will be done through a fecal microbial transplant (FMT). Through oral capsules approved by the FDA for other uses, we will transfer fecal material (poop) from a healthy person to a person with MS. We are seeking 10 to 15 people who are willing to be part of this study.
The goal of this pilot investigational pilot study is to determine whether FMT capsules have the potential to be an effective, safe and tolerable therapy for MS. Before this can ultimately be tested in a larger randomized controlled trial, we first need to gather preliminary data in a small cohort of adults with MS.
We are looking for 10 to 15 people with MS who are 18 - 40 years old, and willing to visit Griffin Hospital 8 times over a 5-month period for:
- A clinical screening to see if they qualify to be part of the study
- A single FMT procedure of 30 capsules taken by mouth on an empty stomach
- 6 other visits for blood and stool samples, physical exams, and filling out surveys
Those who complete their role in the study will be compensated. The FMT capsules, and all study procedures and tests will be provided free of charge.
For information, and to take part in this study at Griffin Hospital in Derby, CT, please call 203-732-1265, ext. 220 for Sue or ext. 300 for Rockiy.